News | November 21, 2024
Siegfried opens global R&D Center for Drug Substances in Switzerland
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Poor oral health (periodontal disease) impacts nearly 51% of Indians
India has taken the lead in recognising NAFLD as a major non-communicable disease
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Subscribe To Our Newsletter & Stay Updated
